Hansa Biopharma AB (publ) at its Annual General Meeting held on June 30, 2022 Peter Nicklin as a new member of the Board of Directors for the period until the end of the next Annual General Meeting.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29.35 SEK | -1.44% | +0.76% | +11.30% |
18/04 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
18/04 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.30% | 174M | |
+22.81% | 46.81B | |
-1.88% | 41.37B | |
+47.07% | 41.29B | |
-6.20% | 28.87B | |
+11.33% | 26.06B | |
-21.00% | 19.13B | |
+30.73% | 12.39B | |
-0.48% | 12.08B | |
-1.43% | 11.96B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB Appoints Peter Nicklin as A New Member of the Board of Director